Efficacy of catumaxomab in tumor spheroid killing is mediated by its trifunctional mode of action

Cancer Immunology, Immunotherapy

Volumn 59, Issue 11, 2010, Pages 1675-1684

  Hirschhaeuser, Franziska ^a   Walenta, Stefan ^a   Mueller Klieser, Wolfgang ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Catumaxomab; Co culture; Immunological tumor therapy Cisplatin; Spheroids; Trifunctional antibody

Indexed keywords

CATUMAXOMAB; CISPLATIN; EPITHELIAL CELL ADHESION MOLECULE; GAMMA INTERFERON; IMMUNOGLOBULIN F(AB) FRAGMENT; INTERLEUKIN 2; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CELL INFILTRATION; CELL VIABILITY; CELL VOLUME; CHEMICAL COMPOSITION; CLONOGENESIS; COCULTURE; COLONY FORMATION; COMPLEX FORMATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG EFFICACY; DRUG POTENTIATION; GROWTH INHIBITION; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; IN VITRO STUDY; MULTICELLULAR SPHEROID; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; TUMOR CELL DESTRUCTION; TUMOR SPHEROID;

ANTIBODIES, BISPECIFIC; ANTIGENS, CD3; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CELL ADHESION MOLECULES; CELL SURVIVAL; CISPLATIN; COCULTURE TECHNIQUES; COMBINED MODALITY THERAPY; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOTHERAPY; SPHEROIDS, CELLULAR; TUMOR CELLS, CULTURED; TUMOR STEM CELL ASSAY;

EID: 77958053173     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-010-0894-1     Document Type: Article

References (36)

1. Zeidler R, Mysliwietz J, Csanady M, Walz A, Ziegler I, Schmitt B, Wollenberg B, Lindhofer H (2000) The Fc-region of a new class of intact bispecific antibody mediates activation of accessory cells and NK cells and induces direct phagocytosis of tumour cells. Br J Cancer 83:261-266
2. Sebastian M, Kuemmel A, Schmidt M, Schmittel A (2009) Catumaxomab: a bispecific trifunctional antibody. Drugs Today 45:589-597
3. Zeidler R, Reisbach G, Wollenberg B, Lang S, Chaubal S, Schmitt B, Lindhofer H (1999) Simultaneous activation of T cells and accessory cells by a new class of intact bispecific antibody results in efficient tumor cell killing. J Immunol 163:1246-1252
4. Riesenberg R, Buchner A, Pohla H, Lindhofer H (2001) Lysis of prostate carcinoma cells by trifunctional bispecific antibodies (alpha EpCAM × alpha CD3). J Histochem Cytochem 49:911-917
5. Piyathilake CJ, Frost AR, Weiss H, Manne U, Heimburger DC, Grizzle WE (2000) The expression of Ep-CAM (17-1A) in squamous cell cancers of the lung. Hum Pathol 31:482-487
6. Balzar M, Winter MJ, Boer CJ, Litvinov SV (1999) The biology of the 17-1A antigen (Ep-CAM). J Mol Med 77:699-712
7. Went P, Dirnhofer S, Schoepf D, Moch H, Spizzo G (2008) Expression and prognostic significance of EpCAM. J Cancer Mol 3(6):169-174
8. Burges A, Wimberger P, Kumper C, Gorbounova V, Sommer H, Schmalfeldt B, Pfisterer J, Lichinitser M, Makhson A, Mois-eyenko V, Lahr A, Schulze E, Jager M, Strohlein MA, Heiss MM, Gottwald T, Lindhofer H, Kimmig R (2007) Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM × anti-CD3 antibody: a phase I/II study. Clin Cancer Res 13:3899-3905
9. Lordick F, Ott K, Weitz J, Jäger D (2008) The evolving role of catumaxomab in gastric cancer. Expert Opin Biol Ther 8:1407-1415
10. Lang S, Wollenberg B, Dellian M, Steuer-Vogt MK, Schwenzer K, Sautier W, Chucholowski M, Eckel R, Faas I, Wilmes E, Ehrenfeld M, Arnold W, Kastenbauer E, Hölzel D (2002) Clinical and epidemiological data of patients with malignomas of the head and neck. Laryngorhinootologie 81:499-508
11. Wollenberg B, Walz A, Kolbow K, Pauli C, Chaubal S, Andratschke M (2004) Clinical relevance of circulating tumour cells in the bone marrow of patients with SCCHN. Onkologie 27:358-362
12. Heiss MM, Strohlein MA, Jager M, Kimmig R, Burges A, Schoberth A, Jauch KW, Schildberg FW, Lindhofer H (2005) Immunotherapy of malignant ascites with trifunctional antibodies. Int J Cancer 117:435-443
13. Ströhlein MA, Siegel R, Jäger M, Lindhofer H, Jauch KW, Heiss MM (2009) Induction of anti-tumor immunity by trifunctional antibodies in patients with peritoneal carcinomatosis. J Exp Clin Cancer Res 28:18
14. Stemmler HJ, Salat C, Lindhofer H, Menzel H, Untch M, Kahlert S, Konecny G, Sauer H, Ledderose G, Heinemann V, Kolb HJ (2005) Combined treatment of metastatic breast cancer (MBC) by high-dose chemotherapy (HDCT) and bispecific antibodies: a pilot study. Anticancer Res 25:3047-3054
15. Sebastian M, Passlick B, Friccius-Quecke H, Jager M, Lindhofer H, Kanniess F, Wiewrodt R, Thiel E, Buhl R, Schmittel A (2007) Treatment of non-small cell lung cancer patients with the trifunctional monoclonal antibody catumaxomab (anti-EpCAM × anti-CD3): a phase I study. Cancer Immunol Immunother 56:1637-1644
16. Riechelmann H, Wiesneth M, Schauwecker P, Reinhardt P, Gronau S, Schmitt A, Schroen C, Atz J, Schmitt M (2007) Adoptive therapy of head and neck squamous cell carcinoma with antibody coated immune cells: a pilot clinical trial. Cancer Immunol Immunother 56:1397-1406
17. Mueller-Klieser W (2000) Tumor biology and experimental therapeutics. Crit Rev Oncol Hematol 36:123-139
18. Uppaluri R, Dunn GP, Lewis JS (2008) Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in head and neck cancers. Cancer Immun 8:16
19. Hirschhaeuser F, Leidig T, Rodday B, Lindemann C, Mueller-Klieser W (2009) Test system for trifunctional antibodies in 3D MCTS culture. J Biomol Screen 14:980-990
20. Yuhas JM, Li AP, Martinez AO, Ladman AJ (1977) A simplified method for production and growth of multicellular tumor spheroids. Cancer Res 37:3639-3643
21. Konur A, Kreutz M, Knuchel R, Krause SW, Andreesen R (1996) Three-dimensional co-culture of human monocytes and macro- phages with tumor cells: analysis of macrophage differentiation and activation. Int J Cancer 66:645-652
22. Lindhofer H, Mocikat R, Steipe B, Thierfelder S (1995) Preferential species-restricted heavy/light chain pairing in rat/mouse quadromas. Implications for a single-step purification of bispecific antibodies. J Immunol 155:219-225
23. Ruf P, Gires O, Jäger M, Fellinger K, Atz J, Lindhofer H (2007) Characterisation of the new EpCAM-specific antibody HO-3: implications for trifunctional antibody immunotherapy of cancer. Br J Cancer 97:315-321
24. Kunz-Schughart LA, Kreutz M, Knuechel R (1998) Multicellular spheroids: a three-dimensional in vitro culture system to study tumour biology. Int J Exp Pathol 79:1-23
25. Gottfried E, Kunz-Schughart LA, Ebner S, Mueller-Klieser W, Hoves S, Andreesen R, Mackensen A, Kreutz M (2006) Tumor-derived lactic acid modulates dendritic cell activation and antigen expression. Blood 107:2013-2021
26. Hoffmann TK, Schirlau K, Sonkoly E, Brandau S, Lang S, Pivarcsi A, Balz V, Muller A, Homey B, Boelke E, Reichert T, Friebe-Hoffmann U, Greve J, Schuler P, Scheckenbach K, Schipper J, Bas M, Whiteside TL, Bier H (2009) A novel mechanism for anti-EGFR antibody action involves chemokine-mediated leukocyte infiltration. Int J Cancer 124:2589-2596
27. Lang S, Atarashi Y, Nishioka Y, Stanson J, Meidenbauer N, Whiteside TL (2000) B7.1 on human carcinomas: costimulation of T cells and enhanced tumor-induced T-cell death. Cell Immunol 201:132-143
28. Schmitt M, Schmitt A, Reinhardt P, Thess B, Manfras B, Lindhofer H, Riechelmann H, Wiesneth M, Gronau S (2004) Opsonization with a trifunctional bispecific (alphaCD3 × alphaEpCAM) antibody results in efficient lysis in vitro and in vivo of EpCAM positive tumor cells by cytotoxic T lymphocytes. Int J Oncol 25:841-848
29. Zeidler R, Mayer A, Gires O, Schmitt B, Mack B, Lindhofer H, Wollenberg B, Walz A (2001) TNFalpha contributes to the antitumor activity of a bispecific, trifunctional antibody. Anticancer Res 21:3499-3503
30. Kiewe P, Hasmuller S, Kahlert S, Heinrigs M, Rack B, Marme A, Korfel A, Jager M, Lindhofer H, Sommer H, Thiel E, Untch M (2006) Phase I trial of the trifunctional anti-HER2 x anti-CD3 antibody ertumaxomab in metastatic breast cancer. Clin Cancer Res 12:3085-3091
31. Li T, He S (2006) Induction of IL-6 release from human T cells by PAR-1 and PAR-2 agonists. Immunol Cell Biol 84:461-466
32. Friedrich J, Seidel C, Ebner R, Kunz-Schughart LA (2009) Spheroid-based drug screen: considerations and practical approach. Nat Protoc 4:309-324
33. Walz A, Mack B, Schmitt B, Gires O, Wollenberg B, Zeidler R (2004) Antitumour effects of a bispecific trivalent antibody in multicellular tumour spheroids. Anticancer Res 24:887-893
34. Muenchen HJ, Aggarwal SK (1998) Immune system activation by cisplatin and its analog 'poly-plat': an in vitro and in vivo study. Anticancer Drugs 9:93-99
35. Okamoto M, Ohe G, Oshikawa T, Nishikawa H, Furuichi S, Yoshida H, Sato M (2000) Induction of cytokines and killer cell activities by cisplatin and 5-fluorouracil in head and neck cancer patients. Anticancer Drugs 11:165-173
36. Gronau SS, Schmitt M, Thess B, Reinhardt P, Wiesneth M, Schmitt A, Riechelmann H (2005) Trifunctional bispecific antibody-induced tumor cell lysis ofsquamous cell carcinomas of the upper aerodigestive tract. Head Neck 27:376-382